Dozens of patients suffered severe harm and received inappropriate chemotherapy for years while under the care of an NHS trust, according to a damning new report. The investigation by the Royal College of Physicians found that individuals treated by University Hospitals Coventry and Warwickshire NHS Trust faced misdiagnoses and received improper courses of treatment.
Some individuals were told they would die if they stopped chemotherapy, even though this claim was completely untrue. In one particular instance, a patient received more than 100 cycles of chemotherapy over 13 years before medical staff identified that the original diagnosis was incorrect. This individual subsequently developed leukaemia as a direct side effect of receiving excessive chemotherapy.
The trust officially apologised for the failures, stating that the care provided fell far below the standards patients deserve and expect. University Hospitals Coventry and Warwickshire NHS Trust commissioned the independent report following the retirement of one of its doctors. The report identified him as Dr Y, while the trust publicly named him as clinical oncologist Professor Ian Brown.
Professor Ian Brown worked at the organisation from 1996 to 2024, and serious concerns regarding his practice emerged when colleagues took over his patients after his retirement in December 2023. Medical staff discovered that patients were being prescribed long-term, repeated cycles of the chemotherapy drug temozolomide. National health guidance urges doctors to prescribe this specific drug for only six cycles, normally spanning six months, or for a maximum of 12 cycles for low-grade gliomas, which are a type of brain tumour.
The report revealed that some patients remained on treatment even while their cancer was actively progressing. The Royal College of Physicians noted multiple examples of extended treatment with temozolomide being continued despite clear evidence of toxicity or deterioration in the patient's condition, with little or no evidence of clinical benefit. The college examined 20 specific cases of patients treated by Professor Ian Brown during the probe.
The review warned that many more patients might be affected, noting that 83 people received extended temozolomide treatment between 2017 and 2023. Among the 20 cases assessed, 15 people received unsatisfactory care, while five cases were graded as requiring improvement. The report concluded that six patients suffered severe harm, five experienced moderate harm, and eight endured low levels of harm. In the final case, the review team could not reach a definitive judgment on moderate or severe harm.
University Hospitals Coventry and Warwickshire NHS Trust Chief Executive Professor Andy Hardy and Trust Chair Sue Noyes stated that meaningful action has been taken to address the concerns. They expressed deep sorrow to all patients and families affected by failures within the neuro-oncology service under the care of retired clinical oncologist Ian Brown. They acknowledged the concern, distress, and loss of trust experienced by individuals during difficult moments of their lives.
The statement explained that the report showed chemotherapy treatment was prolonged beyond accepted national guidance, and opportunities to challenge those clinical decisions sooner were missed. The leadership pair noted that the trust has extended its historical review back to 2005, when national guidance for the drug was first published, to ensure affected patients are identified and supported. The organisation has also taken decisive steps to strengthen clinical governance and ensure all treatment decisions are made collaboratively.
The trust assured anyone currently receiving cancer treatment that care remains safe, effective, and closely monitored by expert cancer teams. A nurse who worked with Professor Ian Brown, identified as Mr N, has retired from the trust, and a formal regulatory referral was submitted to the Nursing and Midwifery Council. A comprehensive independent external clinical review process will evaluate all living patients who received over 12 cycles of the drug under Professor Ian Brown. Discussions have also begun with the NHS England regional director of patient safety to establish clear requirements for reviewing deceased patients who received non-standard chemotherapy regimens.
Former patients have stepped forward in recent months to describe how receiving years of chemotherapy for cancer they never had impacted their lives. Becky Jones claimed she was diagnosed with a grade four glioblastoma brain tumour in 2012 at the age of 21 after experiencing severe migraines. She stated she was given 11 years of chemotherapy prescribed by Professor Ian Brown before discovering she never had cancer, and she is one of more than 40 patients taking legal action against the NHS trust.
David Brown from Atherstone in Warwickshire revealed in January that he was given eight years of unnecessary chemotherapy prescribed by Professor Ian Brown. At the time, David Brown said he went from living a normal, active life involving work and coaching kids' football to becoming completely dependent on his parents for everything. He stated that he trusted the hospital to do what was best for him but cannot understand why he was treated that way for so long, adding that it took everything from him.
Background on the NHS Trust and Temozolomide Guidelines
University Hospitals Coventry and Warwickshire NHS Trust operates major hospitals in the West Midlands region, providing specialist care including neuro-oncology services. National clinical guidelines govern the prescription of temozolomide, a chemotherapy medication primarily used for specific types of brain tumours such as glioblastoma multiform and anaplastic astrocytoma. Medical protocols dictate strict limits on the number of treatment cycles to balance tumour control against the cumulative toxicity risks associated with the drug.
Next Steps for Affected Patients and Legal Actions
The trust continues its expanded historical review and independent external evaluations to identify all individuals who received extended courses of non-standard chemotherapy. Legal representatives for several former patients are progressing civil claims against the healthcare provider following the publication of the Royal College of Physicians findings. Regulatory bodies including the Nursing and Midwifery Council are reviewing referrals related to staff members involved in the disputed treatment decisions.